OrbiMed’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

OrbiMed’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,122,770	Closed	-$30M	–	128
2023 Q4	$30M	Hold	3,122,770	–	–	0.6%	54
2023 Q3	$8.12M	Hold	3,122,770	–	–	0.17%	89
2023 Q2	$14.6M	Hold	3,122,770	–	–	0.26%	76
2023 Q1	$11.8M	Sell	3,122,770 -102,000	-3%	-$402K	0.23%	82
2022 Q4	$10.2M	Hold	3,224,770	–	–	0.19%	74
2022 Q3	$9.71K	Hold	3,224,770	–	–	0.18%	86
2022 Q2	$8.03K	Hold	3,224,770	–	–	0.15%	100
2022 Q1	$25.1M	Hold	3,224,770	–	–	0.41%	60
2021 Q4	$13.4M	Hold	3,224,770	–	–	0.17%	106
2021 Q3	$25.5M	Hold	3,224,770	–	–	0.28%	86
2021 Q2	$26.1M	Hold	3,224,770	–	–	0.26%	88
2021 Q1	$34.6M	Hold	3,224,770	–	–	0.32%	75
2020 Q4	$37.9M	Hold	3,224,770	–	–	0.33%	73
2020 Q3	$38.8M	Hold	3,224,770	–	–	0.49%	59
2020 Q2	$56.3M	Buy	+3,224,770	New	+$56.2M	0.79%	39

Other funds holding FUSN

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's FUSN Position: Q1 2024 in Review

OrbiMed sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 3,122,770 shares — an estimated $30M sold.

OrbiMed first reported a position in FUSN in Q2 2020 and held it in 15 quarters. The position peaked at $56.3M in Q2 2020. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

OrbiMed reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
OrbiMed sold 3,122,770 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $30M.
OrbiMed first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 15 quarters.
OrbiMed's Fusion Pharmaceuticals Inc. Common Shares position peaked at $56.3M in Q2 2020.
114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.